[1] American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders. 5th Edition, American Psychiatric Publishing, Arlington.
[2] Davis, S.M., Stroup, T.S., Koch, G.G., Davis, C.E., Rosenheck, R.A. and Lieberman, J.A. (2011) Time to All-Cause Treatment Discontinuation as the Primary Outcome in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Study. Statistics in Biopharmaceutical Research, 3, 253-265. http://dx.doi.org/10.1198/sbr.2011.10013
[3] Lieberman, J.A., Stroup, T.S., McEvoy, J.P., Swartz, M.S., Rosenheck, R.A., Perkins, D.O., Keefe, R.S., Davis, S.M., Davis, C.E., Lebowitz, B.D., Severe, J. and Hsiao, J.K., for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005) Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. The New England Journal of Medicine, 353, 1209-1223. http://www.nejm.org/doi/full/10.1056/NEJMoa051688
[4] Liu-Seifert, H., Osuntokun, O.O. and Feldman, P.D. (2012) Factors Associated with Adherence to Treatment with Olanzapine and Other Atypical Antipsychotic Medications in Patients with Schizophrenia. Comprehensive Psychiatry, 53, 107-115.
http://dx.doi.org/10.1016/j.comppsych.2010.12.003
[5] Tunis, S.L., Faries, D.E., Nyhuis, A.W., Kinon, B.J., Ascher-Svanum, H. and Aquila, R. (2006) Cost-Effectiveness of Olanzapine as First-Line Treatment for Schizophrenia: Results from a Randomized, Open-Label, 1-Year Trial. Value Health, 9, 77-89.
http://dx.doi.org/10.1111/j.1524-4733.2006.00083.x
[6] Hodgson, R., Belgamwar, R., Al-Tawarah, Y. and MacKenzie, G. (2005) The Use of Atypical Antipsychotics in the Treatment of Schizophrenia in North Staffordshire. Human Psychopharmacology, 20, 141-147.
[7] Jung, S.H., Kim, W.H., Choi, H.J., Kang, M.H., Lee, J.S., Bae, J.N. and Kim, C.E. (2011) Factors Affecting Treatment Discontinuation and Treatment Outcome in Patients with Schizophrenia in Korea: 10-Year Follow-Up Study. Psychiatry Investigation, 8, 22-29. http://dx.doi.org/10.4306/pi.2011.8.1.22
[8] Mullins, C.D., Obeidat, N.A., Cuffel, B.J., Naradzay, J. and Loebel, A.D. (2008) Risk of Discontinuation of Atypical Antipsychotic Agents in the Treatment of Schizophrenia. Schizophrenia Research, 98, 8-15. http://dx.doi.org/10.1016/j.schres.2007.04.035
[9] Gaebel, W., Riesbeck, M., von Wilmsdorff, M., Burns, T., Derks, E.M., Kahn, R.S., Rossler, W. and Fleischhacker, W.W., for the EUFEST Study Group (2010) Drug Attitude as Predictor for Effectiveness in First-Episode Schizophrenia: Results of an Open Randomized Trial (EUFEST). European Neuropsychopharmacology, 20, 310-316. http://dx.doi.org/10.1016/j.euroneuro.2010.02.001
[10] Gianfrancesco, F., Rajagopalan, K., Sajatovic, M. and Wang, R.H. (2006) Treatment Adherence among Patients with Schizophrenia Treated with Atypical and Typical Antipsychotics. Psychiatry Research, 144, 177-189. http://dx.doi.org/10.1016/j.psychres.2006.02.006
[11] Kreyenbuhl, J., Slade, E.P., Medoff, D.R., Brown, C.H., Ehrenreich, B., Afful, J. and Dixon, L.B. (2011) Time to Discontinuation of First- and Second-Generation Antipsychotic Medications in the Treatment of Schizophrenia. Schizophrenia Research, 131, 127-132.
http://dx.doi.org/10.1016/j.schres.2011.04.028
[12] Ye, W., Ascher-Svanum, H., Tanji, Y., Flynn, J.A. and Takahashi, M. (2011) Predictors of Continuation with Olanzapine during the 1-Year Naturalistic Treatment of Patients with Schizophrenia in Japan. Patient Prefer Adherence, 5, 611-617. http://dx.doi.org/10.2147/PPA.S26002
[13] Takahashi, M., Fujikoshi, S., Nakahara, N. and Iyo, M. (2013) The Continuation Rate of Monotherapy with Olanzapine or Other Antipsychotic Drugs in Patients with Acute-Phase Schizophrenia—A 1-Year Observational Study in Routine Clinical Practice. Japanese Journal of Clinical Psychopharmacology, 16, 1649-1660.
[14] San, L., Arranz, B., Perez, V., Safont, G., Corripio, I., Ramirez, N., Duenas, R. and Alvarez, E. (2012) One-Year, Randomized, Open Trial Comparing Olanzapine, Quetiapine, Risperidone and Ziprasidone Effectiveness in Antipsychotic-Naive Patients with a First-Episode Psychosis. Psychiatry Research, 200, 693-701. http://dx.doi.org/10.1016/j.psychres.2012.07.005
[15] Beasley Jr., C.M., Stauffer, V.L., Liu-Seifert, H., Taylor, C.C., Dunayevich, E. and Davis, J.M. (2007) All-Cause Treatment Discontinuation in Schizophrenia during Treatment with Olanzapine Relative to Other Antipsychotics: An Integrated Analysis. Journal of Clinical Psychopharmacology, 27, 252-258.